Click sobre imagen
Roche will hold on to its number three position, but only just. Having been knocked around in the diabetes game for some time, number four Sanofi will come on strong in 2016 as launches of Praluent and dupilumab, along with growtfor Aubagio and Lemtrada, continue to make themselves felt. Merck & Co is secure in the fifth spot, but for sixth place a close race between GlaxoSmithKline and Johnson & Johnson will probably be fought. More bad news from the UK group’s respiratory franchise, or good news from J&J’s Imbruvica partnership with AbbVie, could change this pictur
Roche will hold on to its number three position, but only just. Having been knocked around in the diabetes game for some time, number four Sanofi will come on strong in 2016 as launches of Praluent and dupilumab, along with growtfor Aubagio and Lemtrada, continue to make themselves felt. Merck & Co is secure in the fifth spot, but for sixth place a close race between GlaxoSmithKline and Johnson & Johnson will probably be fought. More bad news from the UK group’s respiratory franchise, or good news from J&J’s Imbruvica partnership with AbbVie, could change this pictur
Gilead
Sciences looks well-established now as the main company that has moved up from
mid-cap biotech into the realm of big pharma, thanks to its hepatitis C
franchise, but this is maturing. Gilead might want to seek to diversify through
an acquisition which could push it up the ranking.
AbbVie and
AstraZeneca round out this list – these two present different pictures of growth,
with Astra slipping down the rankings thanks to patent expiries while AbbVie’s
sales are expanding thanks to its takeout of Pharmacyclics and its cancer drug
Imbruvica
Entradas
No hay comentarios:
Publicar un comentario